Glial suppression and post-traumatic stress disorder: A cross-sectional study of 1,520 world trade center responders
- PMID: 37251545
- PMCID: PMC10209702
- DOI: 10.1016/j.bbih.2023.100631
Glial suppression and post-traumatic stress disorder: A cross-sectional study of 1,520 world trade center responders
Abstract
Background: Chronically re-experiencing the memory of a traumatic event might cause a glial response. This study examined whether glial activation would be associated with PTSD in a study of responders present after the 9/11 World Trade Center attacks without comorbid cerebrovascular disease.
Methods: Plasma was retrieved from 1,520 WTC responders and stored for a cross-sectional sample of responders of varying levels of exposure and PTSD. Plasma levels (pg/ml) of glial fibrillary acidic protein (GFAP) were assayed. Because stroke and other cerebrovascular diseases cause distributional shifts in GFAP levels, multivariable-adjusted finite mixture models analyzed GFAP distributions in responders with and without possible cerebrovascular disease.
Results: Responders were aged 56.3 years and primarily male; 11.07% (n = 154) had chronic PTSD. Older age was associated with increased GFAP, whereas higher body mass was associated with decreased GFAP. Multivariable-adjusted finite mixture models revealed that severe re-experiencing trauma from 9/11 was associated with lower GFAP (B = -0.558, p = 0.003).
Conclusion: This study presents evidence of reduced plasma GFAP levels among WTC responders with PTSD. Results suggest re-experiencing traumatic events might cause glial suppression.
Keywords: Disasters; Glial fibrillary acidic protein; Neuroinflammation; Post-traumatic stress disorder; World trade center.
© 2023 The Authors.
Conflict of interest statement
This is an epidemiological study examining biomarkers associated with posttraumatic stress disorder. The authors have no conflicts of interest to disclose.
Figures


References
-
- Abdelhak A., Foschi M., Abu-Rumeileh S., Yue J.K., D'Anna L., Huss A., Oeckl P., Ludolph A.C., Kuhle J., Petzold A., Manley G.T., Green A.J., Otto M., Tumani H. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 2022;18:158–172. - PubMed
-
- Baker D.G., Ekhator N.N., Kasckow J.W., Hill K.K., Zoumakis E., Dashevsky B.A., Chrousos G.P., Geracioti T.D., Jr. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation. 2001;9:209–217. - PubMed
-
- Bonne O., Gill J.M., Luckenbaugh D.A., Collins C., Owens M.J., Alesci S., Neumeister A., Yuan P., Kinkead B., Manji H.K., Charney D.S., Vythilingam M. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry. 2011;72:1124–1128. - PubMed
Grants and funding
LinkOut - more resources
Miscellaneous